You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTrandolapril
Accession NumberDB00519  (APRD01269)
TypeSmall Molecule
GroupsApproved
DescriptionTrandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment for congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
Structure
Thumb
Synonyms
Mavik
Trandolaprilum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MavikCapsule2 mgOralBgp Pharma Ulc1998-01-14Not applicableCanada
MavikTablet1 mg/1OralAbb Vie Inc.1996-04-26Not applicableUs
MavikCapsule4 mgOralBgp Pharma Ulc2003-11-01Not applicableCanada
MavikTablet2 mg/1OralAbb Vie Inc.1996-04-26Not applicableUs
MavikCapsule0.5 mgOralBgp Pharma Ulc1998-01-28Not applicableCanada
MavikTablet4 mg/1OralAbb Vie Inc.1996-04-26Not applicableUs
MavikCapsule1 mgOralBgp Pharma Ulc1998-01-07Not applicableCanada
MavikTablet4 mg/1OralPhysicians Total Care, Inc.2004-06-25Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TrandolaprilTablet2 mg/1OralEpic Pharma, LLC2015-03-31Not applicableUs
TrandolaprilTablet1 mg/1OralActavis Pharma, Inc.2007-06-12Not applicableUs
TrandolaprilTablet1 mg/1OralTeva Pharmaceuticals USA Inc2007-02-072016-02-29Us
TrandolaprilTablet4 mg/1OralDispensing Solutions, Inc.2007-02-07Not applicableUs
TrandolaprilTablet2 mg/1OralAurobindo Pharma Limited2007-06-12Not applicableUs
TrandolaprilTablet2 mg/1OralAv Kare, Inc.2013-07-302016-10-13Us
TrandolaprilTablet1 mg/1OralCitron Pharma LLC2007-06-12Not applicableUs
TrandolaprilTablet4 mg/1OralEpic Pharma, LLC2015-03-31Not applicableUs
TrandolaprilTablet2 mg/1OralActavis Pharma, Inc.2007-06-12Not applicableUs
TrandolaprilTablet2 mg/1OralTeva Pharmaceuticals USA Inc2007-02-072016-03-31Us
TrandolaprilTablet1 mg/1OralLupin Pharmaceuticals, Inc.2007-06-11Not applicableUs
TrandolaprilTablet4 mg/1OralAurobindo Pharma Limited2007-06-12Not applicableUs
TrandolaprilTablet4 mg/1OralAv Kare, Inc.2013-07-302016-10-13Us
TrandolaprilTablet2 mg/1OralCitron Pharma LLC2007-06-12Not applicableUs
TrandolaprilTablet4 mg/1OralPhysicians Total Care, Inc.2009-08-26Not applicableUs
TrandolaprilTablet4 mg/1OralActavis Pharma, Inc.2007-06-12Not applicableUs
TrandolaprilTablet4 mg/1OralTeva Pharmaceuticals USA Inc2007-02-072016-08-31Us
TrandolaprilTablet2 mg/1OralLupin Pharmaceuticals, Inc.2007-06-11Not applicableUs
TrandolaprilTablet1 mg/1OralCarilion Materials Management2007-06-11Not applicableUs
TrandolaprilTablet1 mg/1OralEpic Pharma, LLC2015-03-31Not applicableUs
TrandolaprilTablet4 mg/1OralCitron Pharma LLC2007-06-12Not applicableUs
TrandolaprilTablet1 mg/1OralAurobindo Pharma Limited2007-06-12Not applicableUs
TrandolaprilTablet1 mg/1OralAv Kare, Inc.2013-07-302016-10-13Us
TrandolaprilTablet4 mg/1OralLupin Pharmaceuticals, Inc.2007-06-11Not applicableUs
TrandolaprilTablet2 mg/1OralCarilion Materials Management2007-02-072016-10-13Us
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
TarkaPhysicians Total Care, Inc.
Trandolapril and Verapamil HydrochlorideGlenmark Pharmaceuticals Inc., Usa
Trandolapril and Verapamil Hydrochloride ERGreenstone LLC
SaltsNot Available
Categories
UNII1T0N3G9CRC
CAS number87679-37-6
WeightAverage: 430.5372
Monoisotopic: 430.246772208
Chemical FormulaC24H34N2O5
InChI KeyVXFJYXUZANRPDJ-WTNASJBWSA-N
InChI
InChI=1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1
IUPAC Name
(2S,3aR,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydro-1H-indole-2-carboxylic acid
SMILES
[H][C@@]12C[[email protected]](N(C(=O)[[email protected]](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O
Pharmacology
IndicationFor the treatment of mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure (CHF), to improve survival following myocardial infarction (MI) in individuals who are hemodynamically stable and demonstrate symptoms of left ventricular systolic dysfunction or signs of CHF within a few days following acute MI, and to slow progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy.
Structured Indications
PharmacodynamicsTrandolapril is the ethyl ester prodrug of a nonsulfhydryl ACE inhibitor, trandolaprilat. Trandolapril is deesterified in the liver to the diacid metabolite, trandolaprilat, which is approximately eight times more active as an inhibitor of ACE than its parent compound. ACE is a peptidyl dipeptidase that is part of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure via a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may further sustain the effects of trandolaprilat by causing increased vasodilation and decreased blood pressure. The blood pressure lowering effect of trandolaprilat is due to a decrease in peripheral vascular resistance, which is not accompanied by significant changes in urinary excretion of chloride or potassium or water or sodium retention.
Mechanism of actionThere are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Trandolaprilat, the active metabolite of trandolapril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Trandolaprilat also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.
TargetKindPharmacological actionActionsOrganismUniProt ID
Angiotensin-converting enzymeProteinyes
inhibitor
HumanP12821 details
Related Articles
Absorption~ 40-60% absorbed; extensive first pass metabolism results in a low bioavailability of 4-14%
Volume of distribution
  • 18 L
Protein bindingSerum protein binding of trandolapril is ~ 80% (independent of concentration and not saturable) while that of trandolaprilat is 65 to 94% (concentration-dependent and saturable).
Metabolism

Cleavage of the ester group of trandolapril, primarily in the liver, is responsible for conversion to trandolaprilat, the active metabolite. Seven other metabolites, including diketopiperazine and glucuronide conjugated derivatives of trandolapril and trandolaprilat, have been identified.

SubstrateEnzymesProduct
Trandolapril
Not Available
DiketopiperazineDetails
Trandolapril
Not Available
TrandolaprilatDetails
Route of eliminationAfter oral administration of trandolapril, about 33% of parent drug and metabolites are recovered in urine, mostly as trandolaprilat, with about 66% in feces.
Half lifeThe elimination half lives of trandolapril and trandolaprilat are about 6 and 10 hours, respectively, but, similar to all ACE inhibitors, trandolaprilat also has a prolonged terminal elimination phase that involves a small fraction of administered drug. This likely represents drug binding to plasma and tissue ACE. The effective half life of elimination for trandolaprilat is 16-24 hours.
Clearance
  • 52 L/h [After approximately 2 mg IV doses]
ToxicityMost likely clinical manifestations of overdose are symptoms of severe hypotension. Most common adverse effects include cough, headache and dizziness. The oral LD50 of trandolapril in mice was 4875 mg/kg in males and 3990 mg/kg in females. In rats, an oral dose of 5000 mg/kg caused low mortality (1 male out of 5; 0 females). In dogs, an oral dose of 1000 mg/kg did not cause mortality and abnormal clinical signs were not observed.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Trandolapril Metabolism PathwayDrug metabolismSMP00599
Trandolapril Action PathwayDrug actionSMP00157
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Trandolapril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Trandolapril.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Trandolapril is combined with Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Trandolapril is combined with Aceclofenac.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Trandolapril is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Trandolapril is combined with Acetovanillone.Investigational
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Trandolapril.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Trandolapril is combined with Adapalene.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Trandolapril.Approved
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Trandolapril.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Trandolapril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Trandolapril.Approved
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Trandolapril.Approved
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Trandolapril.Approved, Illicit, Investigational
AlprenololTrandolapril may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanTrandolapril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Trandolapril.Experimental
AmifostineTrandolapril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Trandolapril is combined with Amiloride.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Trandolapril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Trandolapril.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Trandolapril.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Trandolapril is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Trandolapril.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Trandolapril.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Trandolapril.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Trandolapril is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Trandolapril is combined with Amyl Nitrite.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Antipyrine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Trandolapril is combined with Apremilast.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Trandolapril.Approved, Withdrawn
ArdeparinArdeparin may increase the hyperkalemic activities of Trandolapril.Approved, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Trandolapril.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Trandolapril is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Trandolapril is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Trandolapril.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Trandolapril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Trandolapril is combined with Azapropazone.Withdrawn
AzathioprineTrandolapril may increase the myelosuppressive activities of Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Trandolapril.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Trandolapril is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Trandolapril.Experimental
BarbitalBarbital may increase the hypotensive activities of Trandolapril.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Barnidipine.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Trandolapril.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Trandolapril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Trandolapril.Withdrawn
BenoxaprofenThe risk or severity of adverse effects can be increased when Trandolapril is combined with Benoxaprofen.Withdrawn
BepridilTrandolapril may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Trandolapril.Approved
BethanidineBethanidine may increase the hypotensive activities of Trandolapril.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Trandolapril is combined with Betulinic Acid.Investigational
BimatoprostTrandolapril may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Trandolapril is combined with Bisoprolol.Approved
BoceprevirThe serum concentration of Trandolapril can be decreased when it is combined with Boceprevir.Approved
BortezomibThe risk or severity of adverse effects can be increased when Trandolapril is combined with Bortezomib.Approved, Investigational
BosentanTrandolapril may increase the hypotensive activities of Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Trandolapril is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Trandolapril.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Trandolapril.Approved
BromfenacThe risk or severity of adverse effects can be increased when Trandolapril is combined with Bromfenac.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Trandolapril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Bucillamine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Trandolapril is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Bupivacaine.Approved, Investigational
BupranololTrandolapril may increase the hypotensive activities of Bupranolol.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Trandolapril.Approved
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Trandolapril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Trandolapril.Approved
CandoxatrilTrandolapril may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Captopril.Approved
CarbamazepineThe metabolism of Trandolapril can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Trandolapril is combined with Carbetocin.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Trandolapril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Trandolapril is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Trandolapril is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Trandolapril is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Trandolapril is combined with Celecoxib.Approved, Investigational
CeliprololTrandolapril may increase the hypotensive activities of Celiprolol.Approved, Investigational
CertoparinCertoparin may increase the hyperkalemic activities of Trandolapril.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Trandolapril is combined with Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Trandolapril.Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Trandolapril.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Cilnidipine.Approved
CiprofloxacinTrandolapril may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Trandolapril.Approved, Investigational, Withdrawn
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Trandolapril.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Clofarabine.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Trandolapril.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Clonidine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Trandolapril is combined with Clonixin.Approved
ClozapineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Trandolapril is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Trandolapril.Approved
CryptenamineTrandolapril may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Trandolapril is combined with Curcumin.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Trandolapril.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Trandolapril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Trandolapril.Approved, Investigational, Vet Approved
CyclothiazideTrandolapril may increase the hypotensive activities of Cyclothiazide.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Trandolapril is combined with D-Limonene.Investigational
DalteparinDalteparin may increase the hyperkalemic activities of Trandolapril.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Trandolapril is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Trandolapril.Investigational
DebrisoquinTrandolapril may increase the hypotensive activities of Debrisoquin.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Trandolapril.Approved
dersalazinedersalazine may decrease the antihypertensive activities of Trandolapril.Investigational
DeserpidineTrandolapril may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Trandolapril is combined with Desflurane.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Trandolapril.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Trandolapril.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Trandolapril is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Trandolapril is combined with Diclofenamide.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Trandolapril.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Trandolapril.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Trandolapril.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Trandolapril.Approved
DihydralazineTrandolapril may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Trandolapril.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Trandolapril.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Trandolapril is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Trandolapril is combined with Dipyridamole.Approved
DorzolamideTrandolapril may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Trandolapril.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Trandolapril is combined with Doxazosin.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Trandolapril.Approved
DrospirenoneTrandolapril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Trandolapril is combined with Droxicam.Approved
DuloxetineTrandolapril may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Trandolapril is combined with Duvelisib.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Trandolapril.Approved
E6201The risk or severity of adverse effects can be increased when Trandolapril is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Trandolapril is combined with Ebselen.Investigational
EfonidipineTrandolapril may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Trandolapril is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Enalapril.Approved, Vet Approved
EnalaprilatTrandolapril may increase the hypotensive activities of Enalaprilat.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Trandolapril.Approved, Investigational
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Trandolapril.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Trandolapril is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Trandolapril.Approved
EpoprostenolTrandolapril may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Trandolapril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Trandolapril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Trandolapril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Trandolapril.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Trandolapril.Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Trandolapril.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Trandolapril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Trandolapril.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Trandolapril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Trandolapril.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Trandolapril is combined with Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Trandolapril is combined with Etanercept.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Trandolapril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Trandolapril is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Trandolapril is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Trandolapril is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Trandolapril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Evening primrose oil.Approved
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Trandolapril.Approved
exisulindThe risk or severity of adverse effects can be increased when Trandolapril is combined with exisulind.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Trandolapril is combined with Fenbufen.Approved
FenoldopamTrandolapril may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Trandolapril is combined with Fenoprofen.Approved
FimasartanThe risk or severity of adverse effects can be increased when Trandolapril is combined with Fimasartan.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Trandolapril is combined with Flunixin.Vet Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Trandolapril is combined with Flurbiprofen.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Trandolapril.Experimental
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Trandolapril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Trandolapril.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Trandolapril is combined with Furosemide.Approved, Vet Approved
GarlicThe serum concentration of Trandolapril can be decreased when it is combined with Garlic.Approved
GuanabenzTrandolapril may increase the hypotensive activities of Guanabenz.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Trandolapril.Approved
GuanethidineTrandolapril may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Guanfacine.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Trandolapril is combined with Halothane.Approved, Vet Approved
HeparinHeparin may increase the hyperkalemic activities of Trandolapril.Approved, Investigational
HexamethoniumTrandolapril may increase the hypotensive activities of Hexamethonium.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Trandolapril.Withdrawn
HexobarbitalHexobarbital may increase the hypotensive activities of Trandolapril.Approved
HigenamineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Higenamine.Investigational
HMPL-004The risk or severity of adverse effects can be increased when Trandolapril is combined with HMPL-004.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Trandolapril.Approved
HydralazineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Trandolapril is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideTrandolapril may increase the hypotensive activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Trandolapril is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Trandolapril is combined with Ibuproxam.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Trandolapril.Approved
IloprostIloprost may increase the hypotensive activities of Trandolapril.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Trandolapril.Approved
IndapamideThe risk or severity of adverse effects can be increased when Trandolapril is combined with Indapamide.Approved
IndenololTrandolapril may increase the hypotensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Trandolapril is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Trandolapril is combined with Indoprofen.Withdrawn
IndoraminTrandolapril may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Trandolapril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Trandolapril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Trandolapril.Approved, Investigational
IronThe risk or severity of adverse effects can be increased when Trandolapril is combined with Iron.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Trandolapril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Trandolapril.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Trandolapril is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Trandolapril is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Trandolapril is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Trandolapril is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Trandolapril.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Trandolapril is combined with Kebuzone.Experimental
KetanserinTrandolapril may increase the hypotensive activities of Ketanserin.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Trandolapril is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Trandolapril is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Trandolapril is combined with Labetalol.Approved
LacidipineTrandolapril may increase the hypotensive activities of Lacidipine.Approved
Lanthanum carbonateThe serum concentration of Trandolapril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostTrandolapril may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Trandolapril is combined with Leflunomide.Approved, Investigational
LercanidipineTrandolapril may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Trandolapril is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Levobupivacaine.Approved
LevodopaTrandolapril may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Trandolapril is combined with Levosimendan.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Trandolapril.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Trandolapril.Approved
LofexidineTrandolapril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LornoxicamThe risk or severity of adverse effects can be increased when Trandolapril is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Trandolapril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Trandolapril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Trandolapril is combined with Loxoprofen.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Trandolapril is combined with Lumiracoxib.Approved, Investigational
MacitentanTrandolapril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Trandolapril is combined with Magnesium salicylate.Approved
ManidipineTrandolapril may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Trandolapril is combined with Mannitol.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Trandolapril is combined with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Trandolapril.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Mecamylamine.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Trandolapril is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Trandolapril is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Trandolapril is combined with Meloxicam.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Trandolapril.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Trandolapril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Trandolapril is combined with Metamizole.Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Trandolapril.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Trandolapril is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Trandolapril.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Trandolapril.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Trandolapril is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Trandolapril.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Trandolapril.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Trandolapril.Approved
MetipranololThe risk or severity of adverse effects can be increased when Trandolapril is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Trandolapril is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Trandolapril.Approved, Investigational
MetyrosineTrandolapril may increase the hypotensive activities of Metyrosine.Approved
MibefradilTrandolapril may increase the hypotensive activities of Mibefradil.Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Trandolapril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Trandolapril.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Trandolapril.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Trandolapril.Approved
MizoribineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Trandolapril.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Trandolapril.Approved
MorphineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Morphine.Approved, Investigational
MoxonidineTrandolapril may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Trandolapril is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Trandolapril.Approved
NafamostatThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Naftifine.Approved
NaftopidilTrandolapril may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Trandolapril is combined with Naproxen.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when Trandolapril is combined with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Trandolapril.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Trandolapril.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Trandolapril.Approved
NifedipineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nifedipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Trandolapril is combined with Niflumic Acid.Approved
NiguldipineTrandolapril may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineTrandolapril may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Trandolapril.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Trandolapril.Approved
NitrendipineTrandolapril may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Trandolapril.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Trandolapril.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Trandolapril.Approved
ObinutuzumabTrandolapril may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Trandolapril.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Trandolapril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Olsalazine.Approved
OmapatrilatTrandolapril may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Trandolapril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Trandolapril is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Trandolapril is combined with Oxaprozin.Approved
OxprenololTrandolapril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Trandolapril is combined with Oxyphenbutazone.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Trandolapril is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Papaverine.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Trandolapril is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Trandolapril.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Trandolapril.Approved
PenbutololThe risk or severity of adverse effects can be increased when Trandolapril is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Trandolapril.Approved, Vet Approved
PentoliniumTrandolapril may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Trandolapril.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Trandolapril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Trandolapril.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Trandolapril.Approved
PhenoxybenzamineTrandolapril may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Trandolapril.Withdrawn
PhentolamineTrandolapril may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Trandolapril is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Trandolapril is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Trandolapril.Approved
PinacidilTrandolapril may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Trandolapril is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Trandolapril is combined with Pipamperone.Approved
PiretanidePiretanide may increase the hypotensive activities of Trandolapril.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Trandolapril is combined with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Trandolapril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Trandolapril is combined with Piroxicam.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Trandolapril.Withdrawn
PolythiazideTrandolapril may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Trandolapril is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Trandolapril.Approved
PregabalinThe risk or severity of adverse effects can be increased when Trandolapril is combined with Pregabalin.Approved, Illicit, Investigational
PrimidonePrimidone may increase the hypotensive activities of Trandolapril.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Trandolapril is combined with Propacetamol.Approved
PropofolThe risk or severity of adverse effects can be increased when Trandolapril is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Trandolapril is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Trandolapril.Approved
PTC299The risk or severity of adverse effects can be increased when Trandolapril is combined with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Quinapril.Approved, Investigational
QuinethazoneQuinethazone may increase the hypotensive activities of Trandolapril.Approved
QuinineQuinine may increase the hypotensive activities of Trandolapril.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Trandolapril.Approved
RasagilineRasagiline may increase the hypotensive activities of Trandolapril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Trandolapril.Approved
RescinnamineTrandolapril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Trandolapril.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Trandolapril is combined with Resveratrol.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Trandolapril.Approved
RilmenidineTrandolapril may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Trandolapril.Approved
RisperidoneTrandolapril may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabTrandolapril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Trandolapril is combined with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Trandolapril is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Ropivacaine.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Trandolapril.Approved
RotigotineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Trandolapril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Trandolapril is combined with Salicylamide.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Trandolapril.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Trandolapril is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Trandolapril.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Trandolapril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Trandolapril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Trandolapril.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Trandolapril.Approved, Investigational, Vet Approved
SelexipagTrandolapril may increase the hypotensive activities of Selexipag.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Trandolapril is combined with Seratrodast.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Trandolapril is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Trandolapril.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Trandolapril.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Trandolapril.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Trandolapril.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Trandolapril.Approved, Investigational
SitaxentanTrandolapril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Trandolapril is combined with Sodium aurothiomalate.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Trandolapril is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Trandolapril.Approved
SpiraprilTrandolapril may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Trandolapril.Approved
SRT501The risk or severity of adverse effects can be increased when Trandolapril is combined with SRT501.Investigational
St. John's WortThe metabolism of Trandolapril can be increased when combined with St. John's Wort.Nutraceutical
StreptokinaseThe risk or severity of adverse effects can be increased when Trandolapril is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Sufentanil.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Trandolapril is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Trandolapril is combined with Suprofen.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Trandolapril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Trandolapril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Trandolapril.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Trandolapril is combined with Tamsulosin.Approved, Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Trandolapril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Trandolapril.Approved, Investigational
TemocaprilTrandolapril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Trandolapril is combined with Temsirolimus.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Trandolapril is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Trandolapril is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Trandolapril is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Trandolapril is combined with Teriflunomide.Approved
TerlipressinTrandolapril may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Trandolapril is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Trandolapril.Approved
ThiamylalThiamylal may increase the hypotensive activities of Trandolapril.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Trandolapril.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Thioridazine.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Trandolapril.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Trandolapril is combined with Tiaprofenic acid.Approved
TiboloneTrandolapril may increase the hypotensive activities of Tibolone.Approved
TicrynafenTrandolapril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Trandolapril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Trandolapril.Approved
TipranavirThe serum concentration of Trandolapril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the hypotensive activities of Trandolapril.Approved
TolazolineTrandolapril may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Trandolapril is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Trandolapril is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Trandolapril is combined with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Trandolapril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Trandolapril.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Trandolapril is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Trandolapril.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Trandolapril.Approved
TravoprostTravoprost may increase the hypotensive activities of Trandolapril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Trandolapril.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Trandolapril is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Trandolapril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Trandolapril.Approved
TrichlormethiazideTrandolapril may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrandolapril may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanTrandolapril may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Trandolapril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Trandolapril.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Trisalicylate-choline.Approved
UdenafilUdenafil may increase the antihypertensive activities of Trandolapril.Approved, Investigational
UnoprostoneTrandolapril may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Trandolapril is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Trandolapril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Trandolapril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Trandolapril.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Trandolapril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Trandolapril.Approved, Investigational
VinpocetineTrandolapril may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineTrandolapril may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Trandolapril.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Trandolapril is combined with Zaltoprofen.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Trandolapril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Trandolapril is combined with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Trandolapril is combined with Zomepirac.Withdrawn
Food Interactions
  • Herbs that may attenuate the antihypertensive effect of trandolapril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of trandolapril.
  • Take without regard to meals.
  • Trandolapril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia.
References
Synthesis Reference

Narendra Joshi, Shekhar Bhirud, Buddhavarapu Ramam, Arjun Bodkhe, “Process for the preparation of intermediates of trandolapril and use thereof for the preparation of trandolapril.” U.S. Patent US20060079698, issued April 13, 2006.

US20060079698
General References
  1. Berl T: Review: renal protection by inhibition of the renin-angiotensin-aldosterone system. J Renin Angiotensin Aldosterone Syst. 2009 Mar;10(1):1-8. doi: 10.1177/1470320309102747. [PubMed:19286752 ]
  2. Conen H, Brunner HR: Pharmacologic profile of trandolapril, a new angiotensin-converting enzyme inhibitor. Am Heart J. 1993 May;125(5 Pt 2):1525-31. [PubMed:8480624 ]
  3. Diaz A, Ducharme A: Update on the use of trandolapril in the management of cardiovascular disorders. Vasc Health Risk Manag. 2008;4(6):1147-58. [PubMed:19337528 ]
  4. Guay DR: Trandolapril: a newer angiotensin-converting enzyme inhibitor. Clin Ther. 2003 Mar;25(3):713-75. [PubMed:12852701 ]
  5. Jouquey S, Stepniewski JP, Hamon G: Trandolapril dose-response in spontaneously hypertensive rats: effects on ACE activity, blood pressure, and cardiac hypertrophy. J Cardiovasc Pharmacol. 1994;23 Suppl 4:S16-8. [PubMed:7527096 ]
  6. Reynolds NA, Wagstaff AJ, Keam SJ: Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension. Drugs. 2005;65(13):1893-914. [PubMed:16114984 ]
  7. Rubio-Guerra AF, Vargas-Robles H, Vargas-Ayala G, Rodriguez-Lopez L, Escalante-Acosta BA: The effect of trandolapril and its fixed-dose combination with verapamil on circulating adhesion molecules levels in hypertensive patients with type 2 diabetes. Clin Exp Hypertens. 2008 Oct;30(7):682-8. doi: 10.1080/10641960802251941. [PubMed:18855271 ]
  8. Sanbe A, Tanonaka K, Kobayasi R, Takeo S: Effects of long-term therapy with ACE inhibitors, captopril, enalapril and trandolapril, on myocardial energy metabolism in rats with heart failure following myocardial infarction. J Mol Cell Cardiol. 1995 Oct;27(10):2209-22. [PubMed:8576937 ]
  9. Torp-Pedersen C, Kober L: Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet. 1999 Jul 3;354(9172):9-12. [PubMed:10406358 ]
  10. Authors unspecified: Trandolapril: an ACE inhibitor for treatment of hypertension. Med Lett Drugs Ther. 1996 Nov 22;38(988):104-5. [PubMed:8941256 ]
  11. Wiseman LR, McTavish D: Trandolapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs. 1994 Jul;48(1):71-90. [PubMed:7525196 ]
  12. Zannad F: Trandolapril. How does it differ from other angiotensin converting enzyme inhibitors? Drugs. 1993;46 Suppl 2:172-81; discussion 182. [PubMed:7512472 ]
External Links
ATC CodesC09AA10C09BB10
AHFS Codes
  • 24:32.04
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (57.2 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9303
Blood Brain Barrier-0.8908
Caco-2 permeable-0.8501
P-glycoprotein substrateSubstrate0.7744
P-glycoprotein inhibitor IInhibitor0.5527
P-glycoprotein inhibitor IIInhibitor0.7759
Renal organic cation transporterNon-inhibitor0.8336
CYP450 2C9 substrateNon-substrate0.8227
CYP450 2D6 substrateNon-substrate0.8935
CYP450 3A4 substrateSubstrate0.5515
CYP450 1A2 substrateNon-inhibitor0.915
CYP450 2C9 inhibitorNon-inhibitor0.785
CYP450 2D6 inhibitorNon-inhibitor0.9018
CYP450 2C19 inhibitorNon-inhibitor0.796
CYP450 3A4 inhibitorNon-inhibitor0.5339
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6906
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9188
BiodegradationNot ready biodegradable0.9587
Rat acute toxicity2.2048 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9811
hERG inhibition (predictor II)Non-inhibitor0.5531
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Abbott laboratories pharmaceutical products div
  • Aurobindo pharma ltd
  • Cipla ltd
  • Corepharma llc
  • Dr reddys laboratories ltd
  • Epic pharma llc
  • Invagen pharmaceuticals inc
  • Lupin ltd
  • Mylan pharmaceuticals inc
  • Teva pharmaceuticals usa
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral0.5 mg
CapsuleOral1 mg
CapsuleOral2 mg
CapsuleOral4 mg
TabletOral1 mg/1
TabletOral2 mg/1
TabletOral4 mg/1
Tablet, extended releaseOral
Tablet, film coated, extended releaseOral
Prices
Unit descriptionCostUnit
Tarka 1-240 mg Controlled Release Tabs3.46USD tab
Tarka 4-240 mg Controlled Release Tabs3.4USD tab
Tarka 1-240 mg tablet sa3.33USD tablet
Tarka 2-180 mg tablet sa3.33USD tablet
Tarka 2-240 mg Controlled Release Tabs3.33USD tab
Tarka 2-240 mg tablet sa3.33USD tablet
Tarka 4-240 mg tablet sa3.33USD tablet
Tarka 2-180 mg Controlled Release Tabs3.29USD tab
Mavik 2 mg tablet1.61USD tablet
Mavik 4 mg tablet1.61USD tablet
Mavik 1 mg tablet1.47USD tablet
Trandolapril 1 mg tablet1.24USD tablet
Trandolapril 2 mg tablet1.23USD tablet
Trandolapril 4 mg tablet1.23USD tablet
Mavik 4 mg Capsule1.03USD capsule
Mavik 2 mg Capsule0.83USD capsule
Mavik 1 mg Capsule0.72USD capsule
Mavik 0.5 mg Capsule0.42USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1341206 No2001-03-202018-03-20Canada
CA2023089 No2003-01-142010-08-10Canada
US5744496 No1995-04-282015-04-28Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point119-123 °CNot Available
logP3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0207 mg/mLALOGPS
logP1.31ALOGPS
logP1.95ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)3.8ChemAxon
pKa (Strongest Basic)5.21ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity115.79 m3·mol-1ChemAxon
Polarizability46.79 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentPeptides
Alternative Parents
Substituents
  • Alpha peptide
  • N-acyl-alpha amino acid or derivatives
  • N-acyl-alpha-amino acid
  • Alpha-amino acid ester
  • Alpha-amino acid amide
  • Phenylpropylamine
  • Alpha-amino acid or derivatives
  • N-substituted-alpha-amino acid
  • Indole or derivatives
  • Pyrrolidine carboxylic acid or derivatives
  • Pyrrolidine carboxylic acid
  • N-acylpyrrolidine
  • Aralkylamine
  • Fatty acid ester
  • Fatty acyl
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Tertiary amine
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Piepho RW: Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2000 Oct 1;57 Suppl 1:S3-7. [PubMed:11030016 ]
  3. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Triglyceride lipase activity
Specific Function:
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl-CoA ester. Hydrolyzes the methyl ester group of cocaine to form benzoylecgonine. Catalyzes the transesterification of cocaine to form cocaethylene. Displays fatty acid ethyl ester synthase activity,...
Gene Name:
CES1
Uniprot ID:
P23141
Molecular Weight:
62520.62 Da
References
  1. Zhu HJ, Appel DI, Johnson JA, Chavin KD, Markowitz JS: Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril. Biochem Pharmacol. 2009 Apr 1;77(7):1266-72. doi: 10.1016/j.bcp.2008.12.017. Epub 2009 Jan 6. [PubMed:19185566 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Molecular Weight:
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23